Related Experiment Video
Updated: Jun 12, 2026
08:17
Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
Published on: September 27, 2018
Sacral nerve stimulation for constipation: suboptimal outcome and adverse events.
Yasuko Maeda1, Lilli Lundby, Steen Buntzen
1Surgical Research Unit, Aarhus University Hospital, Aarhus, Denmark. yazmaeda@googlemail.com
Diseases of the Colon and Rectum
|June 17, 2010
Summary
Sacral nerve stimulation for constipation can lead to complications in nearly 60% of patients. While many events are managed by reprogramming, some require surgery or treatment discontinuation.
Area of Science:
- Gastroenterology
- Neurology
- Urology
Background:
- Sacral nerve stimulation (SNS) is an emerging therapy for severe constipation.
- Limited data exists on suboptimal outcomes and complications associated with SNS for constipation.
Purpose of the Study:
- To report a 6-year experience with sacral nerve stimulation (SNS) for constipation.
- To focus on the incidence, management, and outcomes of reportable events in patients undergoing SNS.
Main Methods:
- Retrospective review of patients who received SNS for constipation (August 2002 - September 2008).
- Data collected included demographics, types of suboptimal outcomes and complications, management strategies, and stimulation parameters during events.
Main Results:
- 38 patients received permanent SNS; 58% experienced at least one reportable event.
- Common events included loss of efficacy, pain, and sensory changes.
- 48% of events were managed by reprogramming, 33% required surgery, and 3 events led to discontinuation.
Conclusions:
- Nearly 60% of patients undergoing SNS for constipation experience reportable events.
- Over one-third of these events necessitate surgical intervention or treatment cessation.
- Informed patient consent and systematic assessment are crucial for managing SNS-related events.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...